NEW YORK, April 7, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Acorda Therapeutics Inc. ("Acorda" or the "Company") (NasdaqGS: ACOR).
The investigation focuses on whether the Company and its executives violated federal securities laws in connection with Acorda's Ampyra patents.
On March 31, 2017, the Company announced that U.S. District Judge Leonard Stark of the United States District Court for the District of Delaware invalidated the Company's four patents under U.S. Patent Nos. 8,663,685 (the '685 patent), 8,007,826 (the '826 patent), 8,440,703 (the '703 patent), and 8,354,437 (the '437 patent), which pertain to Ampyra.
On this news, Acorda's share price fell from $26.75 per share on March 30, 2017 to a closing price of $21.00 on March 31, 2017—a $5.75 or a 21.5% drop.
Request more information now by clicking here: www.faruqilaw.com/ACOR. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Acorda's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/acorda-notification-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-investing-in-acorda-therapeutics-inc-to-contact-the-firm-300436765.html
SOURCE Faruqi & Faruqi, LLP